세계의 경피 패치 시장 규모, 점유율, 동향, 예측 : 유형, 유통 채널, 용도, 지역별(2025-2033년)

The global transdermal skin patches market size was valued at USD 8.21 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 11.56 Billion by 2033, exhibiting a CAGR of 3.69% during 2025-2033. North America currently dominates the market, holding a significant market share of 35.5% in 2024. The market is experiencing growth because of advanced healthcare infrastructure supporting innovative transdermal technologies. High prevalence of chronic conditions ensures sustained demand for effective, non-invasive treatment options. Besides this, strong presence of pharmaceutical companies and favorable regulatory frameworks drive product development and regulatory approvals, solidifying the region's significance in the global transdermal skin patches market share.

Transdermal skin patches refer to a non-invasive and easy to use drug delivery method of administering constant and consistent therapeutic dosages into the bloodstream over a predetermined time. They consist of backings, drugs, membranes, adhesives, liners, chemical enhancers and permeators, physical aids, and low electrical current like iontophoresis. They provide a consistent diffusion rate, depending on the characteristics of the skin and the design of the patch. They are nowadays widely used as cosmetic, topical, and transdermal delivery systems around the world.

Transdermal Skin Patches Market Trends:

Transdermal skin patches are effective for treating cardiac and hormonal disorders, migraine, Parkinson's disease, Alzheimer's, stroke, human immunodeficiency virus (HIV), osteoporosis, and restless leg syndrome. Thus, a significant increase in the percentage of the population suffering from these ailments represents one of the key factors impelling the market growth. Moreover, these patches help avoid the traditional oral route for ingesting medicines, lower the inconvenience caused due to intravenous or parenteral therapies, and prevent gastrointestinal toxicity, nausea, and vomiting. Furthermore, due to the ease of administration, transdermal skin patches are gaining traction to improve the compliance of the patient during prolonged treatments for chronic pains and in smoking cessation therapy. Apart from this, the escalating demand for better therapeutics at affordable costs, coupled with a significant rise in the number of clinical trials of different drugs classes, is positively influencing the market. Furthermore, the introduction of pressure-sensitive adhesives and permeation enhancers, which lead to increased product diffusion and enhanced drug retention ability, is anticipated to provide lucrative opportunities to market players and expand the application of transdermal skin patches across the globe in the coming years.

Key Market Segmentation:

Breakup by Type:

• Single-layer Drug-in-Adhesive
• Multi-layer Drug-in-Adhesive
• Matrix
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

Breakup by Application:

• Pain Relief
• Smoking Reduction and Cessation Aid
• Overactive Bladder
• Hormonal Therapy
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, AdhexPharma, LTS Lohmann Therapie-Systeme AG, Luye Pharma Group, Medherant Limited, Nitto Denko Corporation, Noven Pharmaceuticals Inc. (Hisamitsu Pharmaceutical Co. Inc.), Prosolus Inc., Samyang Holdings Corporation, Tapemark, Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd), tesa SE (Beiersdorf AG) and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1.How big is the transdermal skin patches market?
• 2.What is the future outlook of transdermal skin patches market?
• 3.What are the key factors driving the transdermal skin patches market?
• 4.Which region accounts for the largest transdermal skin patches market share?
• 5.Which are the leading companies in the global transdermal skin patches market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transdermal Skin Patches Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Single-layer Drug-in-Adhesive
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Multi-layer Drug-in-Adhesive
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Matrix
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Stores
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Pain Relief
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Smoking Reduction and Cessation Aid
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Overactive Bladder
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Hormonal Therapy
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 3M Company
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AdhexPharma
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 LTS Lohmann Therapie-Systeme AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Luye Pharma Group
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Medherant Limited
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Nitto Denko Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Noven Pharmaceuticals Inc. (Hisamitsu Pharmaceutical Co. Inc.)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Prosolus Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Samyang Holdings Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Tapemark
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd)
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 tesa SE (Beiersdorf AG)
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Teva Pharmaceutical Industries Ltd
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis